Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Akihito Kawazoe,Noboru Yamamoto,Naotoshi Sugimoto,Hisato Kawakami,Takashi Oshima,Kensei Yamaguchi,Kaori Hino,Motohiro Hirao,Yukinori Kurokawa,Takeshi Kawakami,Masahiro Tsuda,Hiroki Hara, Shota Kaname,Daiko Matsuoka,Yohei Otake, Keisuke Yasuda,Takao Takase, Shuya Takashima,Taro Semba,Kei Muro

crossref（2024）

引用 0|浏览1

暂无评分

摘要

Supplementary Fig S3. Percent change in biomarkers at C1D8 (A) and C2D8 (B), pharmacodynamic changes in plasma biomarkers from C1D1 (C), and dichotomized analysis of plasma biomarker levels and PFS (D)

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要